China approves Takeda's diabetes drug Nesina

08/2/2013 | BioSpectrum Asia

Takeda California has obtained an Import Drug License from China's Food and Drug Administration for Nesina, or alogliptin, as treatment for type 2 diabetes. The drug is an orally administered dipeptidyl peptidase-4 inhibitor developed to slow the inactivation of the incretin hormones glucose-dependent insulinotropic peptide and glucagonlike peptide-1.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY